Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20009196 | 0.79 | JAK2 (0.42) | PARP1JAK2JAK1L3MBTL1KLK7 | |
| SCHEMBL16187271 | 0.77 | GPR119 (0.42) | PARP1JAK2JAK1KMT2AL3MBTL1 | |
| SCHEMBL14746164 | 0.76 | KLK7 (0.43) | PARP1JAK2JAK1KMT2AL3MBTL1 | |
| SCHEMBL14746163 | 0.76 | KLK7 (0.43) | PARP1JAK2JAK1KMT2AL3MBTL1 | |
| SCHEMBL19419298 | 0.75 | KLK7 (0.42) | PARP1JAK2JAK1KMT2AL3MBTL1 | |
| SCHEMBL22543395 | 0.75 | KLK7 (0.46) | PARP1JAK2JAK1KMT2AL3MBTL1 | |
| SCHEMBL22543467 | 0.75 | KLK7 (0.46) | PARP1JAK2JAK1KMT2AL3MBTL1 | |
| SCHEMBL15629196 | 0.75 | KLK7 (0.42) | PARP1JAK2JAK1KMT2AL3MBTL1 | |
| SCHEMBL19990672 | 0.74 | JAK2 (0.39) | JAK2JAK1KMT2AL3MBTL1GLA | |
| SCHEMBL14746669 | 0.74 | DPP4 (0.43) | KMT2AL3MBTL1KLK7STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2018-03-29 | — | — | US | disclosed |
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS AG (CH) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086762-A1 | BETA-LACTAMASE INHIBITORS | MGAM, LCT, GAA | PARP1 2554/4885JAK2 4750/4885JAK1 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.